Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Patient Engagement: How Soon Do You Start?

Julie Adrian, European managing director of inVentiv Health Communications, outlines the greatest barriers preventing companies from engaging patients earlier in drug development and highlights the greatest benefits on offer to those that can successfully implement patient-centric drug discovery models.

Market Intelligence Business Strategies Research and Development Strategies

Will Real-World Data Sway Course Of Novel Anticoagulant Market?

A wave of data to support use of novel anticoagulants in real-world settings was presented at the European Society of Cardiology Congress, but the question is whether this will alter the course of the market still dominated by warfarin and trailed by J&J/Bayer's Xarelto.

Cardiovascular Market Intelligence Research & Development

INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve

Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.

Commercial Research & Development Cancer

Surprise! It’s A Phase III Failure

When Phase III clinical trial failures happen it is a painful blow – to the drug manufacturer, to investors and to patients. Scrip takes a look at some of the biggest Phase III surprises since 2010.

Clinical Trials Research & Development Business Strategies

Brexit Effect On Pharma In Numbers: Clinical Trials and EU Funding

The UK, despite its size, is a biotech powerhouse. But a post-Brexit reality will focus on how the country manages to retain its power in uncertain times and without the backing of 27 other member states.

Commercial Brexit Research & Development

World's First Chief Precision Medicine Officer On Using Patient Biology To Shepherd Clinical Trials

"Pharma is throwing the term precision medicine around but it still doesn't really understand what it will take to achieve it," according to the world's first chief precision medicine officer, BERG Health's Michael Kiebish. BERG is combining artificial intelligence and systems biology to analyze stacks of biological data.

Dermatology

Rare Disease Goalposts: A Conundrum For Pharma, FDA

Having clinical trial endpoints that are pragmatic and doable and a clear understanding of what the goalposts are for winning the FDA's approval to get a drug on the market will help decrease the uncertainty and drive investment, said Rakesh Marwah of Palo Alto Investors LLC, a Silicon Valley health care investment firm.

Neurology

How England Is Undermining Clinical Research

Authorities in England are viewing life-extending medicines as "simple commodities like groceries", says Wim Souverijns, general manager of Celgene UK & Ireland. Without a change in attitude, and if plans for a new Cancer Drugs Fund go ahead, companies could decide to relocate their studies from England, although plans for devolution could provide a chink of light for companies, says Souverijns.

Cancer Spain Policy
Advertisement
UsernamePublicRestriction

Register

Advertisement